Ascentage Pharma announced that it releases the latest results from three preclinical studies of its novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development inhibitor APG-5918, at the 2024 American Association of Cancer Research Annual Meeting.
ViroCell Biologics announces that John W. Hadden II, Chief Executive Officer, will be presenting at the annual Cell & Gene Meeting on the Med to be held April 9-11 in Rome, Italy.
ViroCell to present at 2024 Cell & Gene Meeting on the Med Read More »
Laekna announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research in San Diego, California.
Boston Scientific Corporation has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation.
Renalys Pharma, Inc. announced that it has submitted an Investigational New Drug Application for sparsentan to the Pharmaceuticals and Medical Devices Agency for a Phase III clinical trial in Japan.
Los perros han sido los compañeros leales del hombre durante milenios, pero su papel en la sociedad va más allá de la simple amistad. A lo largo de la historia, estos increíbles animales han demostrado una gama asombrosa de habilidades, desde la búsqueda y rescate …
Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers.
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial Read More »
Sensorion announced a €15 million offering reserved to specific categories of investors through the issuance of 24,574,694 new ordinary shares of the Company at a price per New Share of €0.63 to the benefit of existing shareholders including Redmile Group, Invus, Sofinnova Partners and a large investment management firm.
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025 Read More »
En un mundo donde las drogas ilícitas y los productos químicos son objeto de preocupación constante, un peligro menos conocido pero igualmente grave acecha en nuestros hogares y comunidades: la inhalación de pegamento. A menudo subestimado y pasado por alto, inhalar pegam …
Los códigos QR han experimentado un resurgimiento notable en la era digital actual, pasando de ser una curiosidad tecnológica a una herramienta omnipresente en nuestras vidas cotidianas. Estos cuadrados pixelados han encontrado una variedad de aplicaciones innovadoras en campos tan div …
